Phase 2 A, Double-Blind, Randomized, Placebo-Controlled Trial Measuring the Effects of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Plozalizumab (Primary)
- Indications Atherosclerosis
- Focus Pharmacodynamics; Therapeutic Use
- 11 Jul 2008 The completion date for this trial has been identified as Apr 2006.
- 07 Nov 2007 Status changed from in progress to completed.
- 07 Nov 2007 Primary endpoint met; results reported in a Millennium Pharmaceuticals media release.